



PHARMACOLOGY

lecture : # 1 1




DONE BY : Lana Al-Natour

Antiepileptic drugs part

-2-

carbamazepine , phenytoin في هاد التلخيص بدنا نكمل على drugs لانه بالمحاضرة السابقة اخذنا عن : mechanism of action بس بداية نرجع نذكر تقسيمتهم حسب



Sodium channels inhibitors:

3-valproic acid

MOA:

- Blocks Na⁺ channels
- Blocks GABA transaminase (GABA-T)

This enzyme is responsible for metabolism of GABA (so to decrease the degradation of such neurotransmitter, increasing GABA effect because it is an inhibitory NT)

- Blocks T-type Calcium channels

لانه هذول channels الهم دخل في propagation of action potential وبالتالي لما نعملهم block بساعدوا انه AP ما يوصل neurons

Indications:

- Focal seizures • Generalized seizures • Absence seizures • Bipolar disorder

وهاد الدواء بيفرق عن phenytoin / carbamazepine بحيث منقدر نستخدمه في absence seizures ويعتبر first line treatments in absence seizures (in pediatrics)

Pharmacokinetics:

- **Inhibits** CYP2C9, UGT, epoxide hydroxylase
drug-drug interactions وبالتالي فيه عكس phenytoin / carbamazepine

Adverse effects:

- Hepatotoxicity

Used in caution in patients with liver disease

- Teratogenicity

Contraindicated in pregnant woman because it results in massive congenital abnormalities and cognitive deficits in new-born

- CNS-related

*we have different preparations in valproic acid because there is a problem in absorption in GIT(acidity)

other preparations like sodium valproate فعشان هيك عنا

efficacy but different pharmacokinetics الهم نفس

Valproic acid vs Sodium valproate vs Divalproex sodium

4-lamotrigine

One of the most important drugs that is used in epilepsy usually in most of the cases is considered as first line drug depending on the factors(type of seizure....)

MOA:

- Blocks Na⁺ channels
- Blocks voltage-gated Ca⁺⁺ channels

Indications:

- Focal seizures
- Generalized seizures
- Absence seizures
- Lennox-Gastaut syndrome

Sever epilepsy syndromes (epilepsy other neurological disorders)

- Bipolar disorder

منستخدم هاد الدواء ك mood stabilizer اكثر من valproic acid and carbamazepine فعشان كمان هو safe drug

Pharmacokinetics:

- Metabolized by UGT(in the liver)
- What will happen when combined with :

phenytoin?

الدكتور سأل لو مثلا مريض ما استجاب على lamotrigine لحاله فانت لازم هيك تعمل combination with other drug فمثلا انت اعطيته مع phenytoin هلا شو ممكن يصير بال lamotrigine levels لما اخذه مع phenytoin ??

رح يقل تركيزه ليش؟ لانه phenytoin بزود هاد enzyme وهو UGT inducer وبالتالي رح يزيد metabolism of lamotrigine

وبالتالي انا لما اعطي lamotrigine مع phenytoin لازم ازود dose تااعت lamotrigine

Valproic acid?

طيب سوال ثاني لو اعطينا valproic acid مع lamotrigine شو رح يصير بال ? lamotrigine levels
رح يزيد تركيزه لانه valproic acid عبارة عن (UGT) enzyme inhibitor
وبالتالي لازم اقلل dose لما اعطيه مع valproic acid

Adverse effects:

• CNS-related side effects (headache,dizziness, drowsiness)

-Severe skin reaction (lifethreatening)(rare)

هون لازم احذر المريض اذا اجا skin rash لازم ييجي على الطوارئ

5- Topiramate

MOA:

- Blocks Na⁺ channels
- Blocks L-type Calcium channels
- Carbonic anhydrase inhibitor
- NMDA blocker(glutamate receptor)(because if we want to reduce the activity of the brain we have to antagonize the Glutamate ,to inhibit the signalling)

Indications:

- Focal seizures
- Generalized seizures
- Migraine prevention (prophylactic)

Pharmacokinetics:

- Inhibits CYP2C9

Adverse effects

- Somnolence(increase sleeping)
- Weight loss
- Paresthesia
- Renal stones
- Oligohidrosis (reduced sweating,dry skin)
- hyperthermia

عنده شوية adverse effects ما الها دخل ببعض عشان عنده mechanism of actions مختلفة

6- Zonisamide

MOA:

- Blocks Na⁺ channels
- Blocks T-type Calcium channels
- Limited carbonic anhydrase inhibitor

In order to inhibit action potential propagation

Indications:

- Focal seizures

Not used in generalized seizures

Adverse effects

- CNS adverse effects
- Nephrolithiasis (kidney stones)
- Oligohidrosis
- Contraindicated in patients with sulfonamide hypersensitivity (because it has sulpha group)

calcium channel inhibitors:

Ethosuximide:

MOA:

- Blocks T-type Calcium channels

Indications:

- Absence seizure only
(Drug of choice)

Pharmacokinetics:

Half-life: 30-60 hrs (longer half -life)

To sum up : how many drugs till now are used in absence seizures :

- 1-ethosuximide
- 2-valproic acid
- 3-lamotrigine

Increase in GABA transmission drugs :

-Benzodiazepines

Phenobarbital

MOA:

- Bind to GABA_A receptors and enhance GABA binding → facilitates Chloride entry
→inhibitory

Indications:

- Clonazepam → adjunctive antiseizure therapy

first line drugs هما مش

- Diazepam → status

Epilepticus ((state of continues seizure)) (drug of choice)

-Gabapentin

Pregabalin

MOA:

- Analog of GABA
- It does NOT act at GABA receptor
- MOA is unknown

Homework :possible mechanism of action of gabapentin: ((google))

mechanism of action as an antiepileptic agent likely involves its inhibition of the alpha 2-delta subunit of voltage-gated calcium channels

Indications:

- Adjunct therapy for focal seizures
- Neuropathic pain, e.g., postherpetic neuralgia, diabetic neuropathy(in diabetes)

Pharmacokinetics:

- Secreted unchanged
- Few drug interactions
- Suitable for elderly

It is not the best choice in renal impairment

Adverse effects

- Sedation

Euphoria (so some people start to abuse such drug)

- Felbamate

MOA:

- Blocks voltage-gated Na⁺ channels
- Blocks NMDA receptors
- Blocks Ca⁺⁺ channels
- Potentiates GABA

Indications:

- Reserved for refractory epilepsy

مثلا في الحالات يلي يكون المريض ياخذ فيها lamotrigine اذا ما استجاب عليها منسخدم فيها بال combinations هاد الدواء

- Lennox-Gastaut syndrome((sever epilepsy cases))

Pharmacokinetics:

- Inhibits CYP2C19
- Induces CYP3A4

بشبهه valproic acid

Adverse effects:

- Aplastic anemia ((sever))
- Hepatic failure

Dangerous drug •

So it is not first line ,so it is not frequently used for example in comparing with lamotrigine in which is important and useful drug

Others :

- Ezogabine

MOA:

- Open voltage-gated M-type potassium channels → stabilizing resting membrane potential

It will hyperpolarized the membrane (so in that way the excitability will be reduced)

Pharmacokinetics:

- No drug interactions at low doses

Adverse effects

- Urinary retention
- QT interval prolongation
- Blue skin discoloration

Retinal abnormalities ((effect vision))•

- Levetiracetam

Very effective and commonly used ,widely used

MOA:

- unknown

Indications:

- **Focal (simple and complex) seizures**
- Adjunct therapy for **generalized seizures**

Adverse effects

- Dizziness
- somnolence •

Status Epilepticus

- Continuous or repetitive seizures (> 20 min) with impaired consciousness during the interictal period.

هنا معظم seizures عبارة عن self-limited وتبطل ولكن لو صار progress of seizures بسرعة لازم يروح على الطوارئ

- Management

1. Diazepam (IV or rectal) → for rapid control.
2. Fosphenytoin (prodrug) or phenytoin → long-acting, to maintain control.
3. Phenobarbital → 2nd choice to phenytoin.

هنا هون افترض انه 3 choices of drugs ما زبطوا بدخل المريض في coma ومنعطي anesthetics


4. Propofol (IV anesthesia) → **in resistant cases.**

Antiepileptics during pregnancy

- **Monotherapy**

عشان combination رح يكون عنا adverse effects


- The lowest possible dose
- **Lamotrigine; gabapentin = safe**
- **Valproic acid; phenobarbital; phenytoin, others = contraindicated**
- Cleft lip, neural tube defect (patients considering pregnancy while on antiepileptics should receive folic acid supplements)



مثلا مريضة كان معها epilepsy واخذت ادوية زي valproic acid وكانت control وبعدها طلعت حامل؟ شو الاجراء يلي لازم ينعمل؟

انه نسوي switch ونعطيه safe drugs

Summary of Therapeutic Strategy



لازم نعمل proper diagnose وبناء عليه نعطي monotherapy و lowest dose و اذا patient صار له لمدة سنيتين على control single therapy ومنبش نسوي termination gradually

AAN Guidelines for Epilepsy Treatment

| Level | Recommendation |
|--|--|
| Level B | LTG use should be considered to decrease seizure frequency. |
| Levels B and Level C | LTG use should be considered (Level B) and GBP use may be considered (Level C) to decrease seizure frequency in patients aged ≥60 years. |
| Level C | LEV use may be considered to decrease seizure frequency. |
| Level C | ZNS use may be considered to decrease seizure frequency. |
| Level C | VGB use appears to be less efficacious than immediate-release carbamazepine (CBZ) use and may not be offered; furthermore, toxicity profile precludes VGB use as first-line therapy. |
| Level C | PGB use at 150 mg/d is possibly less efficacious than LTG use at 100 mg/d. |
| Level U | Evidence is insufficient to consider GBP, OXC, or TPM instead of CBZ. |
| Level U | Evidence is insufficient to consider TPM instead of phenytoin in urgent treatment of new-onset or recurrent focal epilepsy, unclassified generalized tonic-clonic (GTC) seizures, or generalized epilepsy (GE) presenting with GTC seizures. |
| Level U | Data are lacking to support or refute use of third-generation AEDs, CLB, FBM, or VGB in treating new-onset epilepsy. |
| Level U | Data are lacking to support or refute use of newer AEDs in treating unclassified GTC seizures. |
| Recommendation for childhood absence epilepsy | |
| Level | Recommendation |
| Level B | Unless there are compelling reasons based on adverse events (AEs) profile, ethosuximide (ETS) or VPA use should be considered before LTG use to decrease seizure frequency in treating absence seizures in childhood absence epilepsy. |


LTG: lamotrigine

antiepileptic drugs **هول levels لكل**

الدكتور ركز على **تاع level B (absence seizure) فمممكن يجيب case عليها ☺

فيه جدول مهم حكا عنه الدكتور من الكتاب ويسأل عنه ب cases :

كل type of seizure كيف منبلش نعالجها بأي antiepileptic drugs



Summary of the drugs :

| DRUG | MECHANISM OF ACTION | ADVERSE EFFECTS AND COMMENTS |
|-------------------------|----------------------------------|--|
| Carbamazepine | Blocks Na ⁺ channels | Hyponatremia, drowsiness, fatigue, dizziness, and blurred vision. Drug use has also been associated with Stevens Johnson syndrome. Blood dyscrasias: neutropenia, leukopenia, thrombocytopenia, pancytopenia, and anemia. |
| Divalproex | Multiple mechanisms of action | Weight gain, easy bruising, nausea, tremor, hair loss, GI upset, liver damage, alopecia, and sedation. Hepatic failure, pancreatitis, and teratogenic effects have been observed. Broad spectrum of antiepileptic activity. |
| Eslicarbazepine acetate | Blocks Na ⁺ channels | Nausea, rash, hyponatremia, headache, sedation, dizziness, vertigo, ataxia, and diplopia. |
| Ethosuximide | Blocks Ca ²⁺ channels | Drowsiness, hyperactivity, nausea, sedation, GI upset, weight gain, lethargy, SLE, and rash. Blood dyscrasias can occur: periodic CBCs should be done. Abrupt discontinuance of drug may cause seizures. |
| Ezogabine | Enhances K ⁺ channels | Urinary retention, neuropsychiatric symptoms, dizziness, somnolence, QT prolongation, reports of blue skin discoloration, and retina changes. |
| Falbamate | Multiple mechanisms of action | Insomnia, dizziness, headache, ataxia, weight gain, and irritability. Aplastic anemia and hepatic failure. Broad spectrum of antiepileptic activity. Requires patient to sign informed consent at dispensing. |
| Gabapentin | Unknown | Mild drowsiness, dizziness, ataxia, weight gain, and diarrhea. Few drug interactions. One hundred percent renal elimination. |
| Lacosamide | Multiple mechanisms of action | Dizziness, fatigue, and headache. Few drug interactions: Schedule V. |
| Lamotrigine | Multiple mechanisms of action | Nausea, drowsiness, dizziness, headache, and diplopia. Rash (Stevens-Johnson syndrome—potentially life threatening). Broad spectrum of antiepileptic activity. |
| Levetiracetam | Multiple mechanisms of action | Sedation, dizziness, headache, anorexia, fatigue, infection, and behavioral symptoms. Few drug interactions. Broad spectrum of antiepileptic activity. |
| Oxcarbazepine | Blocks Na ⁺ channels | Nausea, rash, hyponatremia, headache, sedation, dizziness, vertigo, ataxia, and diplopia. |
| Perampamil | Blocks AMPA glutamate receptors | Serious psychiatric and behavioral reactions, dizziness, somnolence, fatigue, gait disturbance, and falls. Long half-life. |
| Phenytoin | Blocks Na ⁺ channels | Gingival hyperplasia, confusion, blurred speech, double vision, ataxia, sedation, dizziness, and hirsutism. Stevens-Johnson syndrome—potentially life threatening. Not recommended for chronic use. Primary treatment for status epilepticus (fosphenytoin). |
| Pregabalin | Multiple mechanisms of action | Weight gain, somnolence, dizziness, headache, diplopia, and ataxia. One hundred percent renal elimination. |
| Rufinamide | Unknown | Shortened QT interval. Multiple drug interactions. |
| Tiagabine | Blocks GABA uptake | Sedation, weight gain, fatigue, headache, tremor, dizziness, and anorexia. Multiple drug interactions. |
| Topiramate | Multiple mechanisms of action | Paresthesia, weight loss, nervousness, depression, anorexia, anxiety, tremor, cognitive complaints, headache, and oligohydrosis. Few drug interactions. Broad spectrum of antiepileptic activity. |
| Vigabatrin | Irreversible binding of GABA-T | Vision loss, anemia, somnolence, fatigue, peripheral neuropathy, weight gain. Available only through SHARED pharmacies. |
| Zonisamide | Multiple mechanisms of action | Nausea, anorexia, ataxia, confusion, difficulty concentrating, sedation, paresthesia, and oligohydrosis. Broad spectrum of antiepileptic activity. |

| ANTI-EPILEPSY MEDICATION | PROTEIN BINDING* | HALF-LIFE | ACTIVE METABOLITE | MAJOR ORGAN OF ELIMINATION | DRUG INTERACTIONS |
|-----------------------------|------------------|-----------|-----------------------------------|----------------------------|-------------------|
| Carbamazepine | Moderate | 6-15 | CBZ-10,11-epoxide | Liver | ✓ |
| Eslicarbazepine acetate **A | Low | 8-24 | Eslicarbazepine (S-licarbazepine) | Kidney | ✓ |
| Ethosuximide | Low | 25-26 | | Liver | ✓ |
| Ezogabine | Moderate | 7-11 | monoacetylated metabolite | Liver | ✓ |
| Falbamate | Low | 20-23 | | Kidney/Liver | ✓ |
| Fosphenytoin** | High | 12-60 | phenytoin | Liver | ✓ |
| Gabapentin | Low | 5-9 | | Kidney | ✓ |
| Lacosamide | Low | 13 | | Various | ✓ |
| Lamotrigine | Low | 25-32 | | Liver | ✓ |
| Levetiracetam | Low | 6-8 | | Hydrolysis | ✓ |
| Oxcarbazepine** | Low | 5-13 | Monohydroxy metabolite (MHD) | Liver | ✓ |
| Phenobarbital | Low | 72-124 | | Liver | ✓ |
| Phenytoin | High | 12-60 | | Liver | ✓ |
| Primidone | High | 72-124 | Phenobarbital, PEMA | Liver | ✓ |
| Perampamil ^A | High | 105 | | Liver | ✓ |
| Pregabalin | Low | 5-6.5 | | Kidney | ✓ |
| Rufinamide | Low | 6-10 | | Liver | ✓ |
| Tiagabine | High | 7-9 | | Liver | ✓ |
| Topiramate | Low | 21 | | Various | ✓ |
| Vigabatrin | Low | 7.5 | | Kidney | ✓ |
| Valproic Acid (Divalproex) | Moderate/High | 6-18 | Various | Liver | ✓ |
| Zonisamide | Low | 63 | | Liver | ✓ |

Questions :

Several classes of antiepileptic drugs (AEDs) interfere with the propagation of action potentials in hyperactive epileptic foci by inhibiting the activation of voltage-gated Na⁺ channels. All of the following medications share this mechanism of action, EXCEPT:

- Zonisamide
- Carbamazepine
- Conazepam
- Valproic acid
- Phenytoin

answer:C

All of the following mechanisms of action account for the antiepileptic effects of the drug topiramate, EXCEPT:

- Voltage-gated Na⁺ channel blockade
- L-type Ca⁺⁺ channel blockade
- Carbonic anhydrase inhibition
- Glutamate NMDA receptor antagonist
- Facilitation of Cl⁻ influx at GABA receptor

answer : e

Name an AED that is associated with each of the following adverse effects

| | | |
|--|--|---|
|  Sedation Phenobarbital |  Rash Lamotrigine |  Weight gain or weight loss Topiramate |
|  Ataxia Phenytoin |  Hyponatremia Carbamazepine |  Teratogenicity |

Good luck 😊